Edition:
United States

Pluristem Therapeutics Inc (PSTI.OQ)

PSTI.OQ on NASDAQ Stock Exchange Capital Market

1.32USD
18 Sep 2018
Change (% chg)

$0.03 (+2.33%)
Prev Close
$1.29
Open
$1.27
Day's High
$1.34
Day's Low
$1.27
Volume
35,532
Avg. Vol
64,302
52-wk High
$2.12
52-wk Low
$1.15

Select another date:

Tue, Jun 12 2018

Photo

Israel's Pluristem sees positive results from leg pain study

TEL AVIV Israel's Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said on Tuesday it had positive results from a mid-stage study of its therapy to treat leg pain known as intermittent claudication (IC).

Israel's Pluristem sees positive results from leg pain study

TEL AVIV, June 12 Israel's Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said on Tuesday it had positive results from a mid-stage study of its therapy to treat leg pain known as intermittent claudication (IC).

FDA clears Pluristem radiation treatment for emergency use

HAIFA, Israel Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said the U.S. Food and Drug Administration has cleared the emergency use of its therapy to treat acute radiation exposure in a nuclear event.

FDA clears Pluristem radiation treatment for emergency use

HAIFA, Israel, April 30 Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said the U.S. Food and Drug Administration has cleared the emergency use of its therapy to treat acute radiation exposure in a nuclear event.

BRIEF-U.S. FDA Clears Pluristem’S Phase III Study In Treatment Of Muscle Injury Following Hip Fracture Surgery

* U.S. FDA CLEARS PLURISTEM’S PHASE III STUDY IN TREATMENT OF MUSCLE INJURY FOLLOWING HIP FRACTURE SURGERY

Select another date: